AEs	Adverse events
AMD	Age-related macular degeneration
Anti-VEGF	Vascular endothelial growth factor inhibitors
AREDS	Age-Related Eye Disease Study
ASRS	American Society of Retina Specialists
BCVA	Best corrected visual acuity
BLA	Biologics License Application
CANTREAT	Canadian Treat-and-Extend Analysis Trial with ranibizumab
CATT	Comparison of Age-Related Macular Degeneration Treatments Trials
CMT	Central macular thickness
CNV	Choroidal new vessels
DARPin	Designed ankyrin repeat protein
DME	Diabetic macular edema
EMAs	European Medicines Agency
ETDRS	Early Treatment Diabetic Retinopathy Study
FDA	Food and Drug Administration
GA	Geography atrophy
HIF-1	Hypoxia-inducible factor-1
IFSR	Intravitreal fluocinolone sustained released
IOI	Intraocular inflammation
ISIS	Intelligent Research in Sight
IVT-AFL	Intravitreal aflibercept
IVT-AFL-2W	Intravitreal aflibercept administered every 2 weeks
IVT-AFL-4W	Intravitreal aflibercept administered every 4 weeks
MAC	Membrane attack complex
MMP	Metalloproteinase
NVAMD	Neovascular age-related macular degeneration
OCT	optical coherence tomography
PDGF-B	Platelet-derived growth factor-B
PIGF	Placental growth factor
PMDA	Japanese Regulatory Agency
PRN	Pro re nata
Q4	Every 4 weeks
Q8	Every 8 weeks
Q12	Every 12 weeks
RCT	Randomized clinical trial
RPE	Retinal pigment epithelium
RQ4	Intravitreal ranibizumab administered every 4 weeks
SDF-1	Stromal-derived factor-1
TIMP	Tissue inhibitor of metalloproteinases
TREX	Treat-and-extend
VA	visual acuity
VEGF	Vascular endothelial growth factor